-
Something wrong with this record ?
Khellin and visnagin differentially modulate AHR signaling and downstream CYP1A activity in human liver cells
R. Vrzal, K. Frauenstein, P. Proksch, J. Abel, Z. Dvorak, T. Haarmann-Stemmann,
Language English Country United States
Document type Journal Article, Research Support, Non-U.S. Gov't
NLK
Directory of Open Access Journals
from 2006
Free Medical Journals
from 2006
Public Library of Science (PLoS)
from 2006
PubMed Central
from 2006
Europe PubMed Central
from 2006
ProQuest Central
from 2006-12-01
Open Access Digital Library
from 2006-01-01
Open Access Digital Library
from 2006-01-01
Open Access Digital Library
from 2006-10-01
Medline Complete (EBSCOhost)
from 2008-01-01
Nursing & Allied Health Database (ProQuest)
from 2006-12-01
Health & Medicine (ProQuest)
from 2006-12-01
Public Health Database (ProQuest)
from 2006-12-01
ROAD: Directory of Open Access Scholarly Resources
from 2006
- MeSH
- Enzyme Activation drug effects MeSH
- Aryl Hydrocarbon Hydroxylases metabolism MeSH
- Cell Line MeSH
- Cytochrome P-450 CYP1A1 genetics metabolism MeSH
- Gene Expression MeSH
- Hepatocytes drug effects metabolism MeSH
- Khellin pharmacology MeSH
- Humans MeSH
- Receptors, Aryl Hydrocarbon metabolism MeSH
- Gene Expression Regulation drug effects MeSH
- Genes, Reporter MeSH
- Signal Transduction drug effects MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
Khellin and visnagin are two furanochromones that can be frequently found in ethnomedical formulations in Asia and the Middle East. Both compounds possess anti-inflammatory and analgesic properties, therefore modern medicine uses these compounds or structurally related derivatives for treatment of vitiligo, bronchial asthma and renal colics. Despite their frequent usage, the potential toxic properties of visnagin and khellin are not well characterized up-to-now. Many natural compounds modulate the expression and activity of cytochrome P450 1A1 (CYP1A1), which is well-known to bioactivate pro-carcinogens. The expression of this enzyme is controlled by the aryl hydrocarbon receptor (AHR), a ligand-activated transcription factor and regulator of drug metabolism. Here, we investigated the influence of both furanochromones on AHR signaling in human HepG2 hepatocarcinoma cells and primary human hepatocytes. Both compounds transactivated xenobiotic response element (XRE)-driven reporter gene activity in a dose-dependent manner and induced CYP1A1 transcription in HepG2 cells and primary hepatocytes. The latter was abolished in presence of a specific AHR antagonist. CYP1A enzyme activity assays done in HepG2 cells and primary hepatocytes revealed an inhibition of enzyme activity by both furanochromones, which may become relevant regarding the metabolism of xenobiotics and co-administered therapeutic drugs. The observed induction of several other members of the AHR gene battery, whose gene products are involved in regulation of cell growth, differentiation and migration, indicates that a further toxicological characterization of visnagin and khelllin is urgently required in order to minimize potential drug-drug interactions and other toxic side-effects that may occur during therapeutic usage of these furanochromones.
Department of Cell Biology and Genetics Faculty of Science Palacky University Olomouc Czech Republic
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc14063937
- 003
- CZ-PrNML
- 005
- 20140707113459.0
- 007
- ta
- 008
- 140704s2013 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1371/journal.pone.0074917 $2 doi
- 035 __
- $a (PubMed)24069365
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Vrzal, Radim $u Department of Cell Biology and Genetics, Faculty of Science, Palacky University, Olomouc, Czech Republic.
- 245 10
- $a Khellin and visnagin differentially modulate AHR signaling and downstream CYP1A activity in human liver cells / $c R. Vrzal, K. Frauenstein, P. Proksch, J. Abel, Z. Dvorak, T. Haarmann-Stemmann,
- 520 9_
- $a Khellin and visnagin are two furanochromones that can be frequently found in ethnomedical formulations in Asia and the Middle East. Both compounds possess anti-inflammatory and analgesic properties, therefore modern medicine uses these compounds or structurally related derivatives for treatment of vitiligo, bronchial asthma and renal colics. Despite their frequent usage, the potential toxic properties of visnagin and khellin are not well characterized up-to-now. Many natural compounds modulate the expression and activity of cytochrome P450 1A1 (CYP1A1), which is well-known to bioactivate pro-carcinogens. The expression of this enzyme is controlled by the aryl hydrocarbon receptor (AHR), a ligand-activated transcription factor and regulator of drug metabolism. Here, we investigated the influence of both furanochromones on AHR signaling in human HepG2 hepatocarcinoma cells and primary human hepatocytes. Both compounds transactivated xenobiotic response element (XRE)-driven reporter gene activity in a dose-dependent manner and induced CYP1A1 transcription in HepG2 cells and primary hepatocytes. The latter was abolished in presence of a specific AHR antagonist. CYP1A enzyme activity assays done in HepG2 cells and primary hepatocytes revealed an inhibition of enzyme activity by both furanochromones, which may become relevant regarding the metabolism of xenobiotics and co-administered therapeutic drugs. The observed induction of several other members of the AHR gene battery, whose gene products are involved in regulation of cell growth, differentiation and migration, indicates that a further toxicological characterization of visnagin and khelllin is urgently required in order to minimize potential drug-drug interactions and other toxic side-effects that may occur during therapeutic usage of these furanochromones.
- 650 _2
- $a aromatické hydroxylasy $x metabolismus $7 D001189
- 650 _2
- $a buněčné linie $7 D002460
- 650 _2
- $a cytochrom P-450 CYP1A1 $x genetika $x metabolismus $7 D019363
- 650 _2
- $a aktivace enzymů $x účinky léků $7 D004789
- 650 _2
- $a exprese genu $7 D015870
- 650 _2
- $a regulace genové exprese $x účinky léků $7 D005786
- 650 _2
- $a reportérové geny $7 D017930
- 650 _2
- $a hepatocyty $x účinky léků $x metabolismus $7 D022781
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a khelin $x farmakologie $7 D007666
- 650 _2
- $a receptory aromatických uhlovodíků $x metabolismus $7 D018336
- 650 _2
- $a signální transdukce $x účinky léků $7 D015398
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Frauenstein, Katrin
- 700 1_
- $a Proksch, Peter
- 700 1_
- $a Abel, Josef $7 gn_A_00000524
- 700 1_
- $a Dvorak, Zdenek
- 700 1_
- $a Haarmann-Stemmann, Thomas
- 773 0_
- $w MED00180950 $t PloS one $x 1932-6203 $g Roč. 8, č. 9 (2013), s. e74917
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/24069365 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20140704 $b ABA008
- 991 __
- $a 20140707113747 $b ABA008
- 999 __
- $a ok $b bmc $g 1031421 $s 862669
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2013 $b 8 $c 9 $d e74917 $i 1932-6203 $m PLoS One $n PLoS One $x MED00180950
- LZP __
- $a Pubmed-20140704